HIV Medicine

Article	Citations
	148
Issue Information	94
	75
	70
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co‐administration	49
HIV ‐1 viral load and reservoir size remain stable following SARS ‐ CoV	46
Issue Information	46
Disparities in HIV continuum of care in the paediatric population: A real‐life study in Brazil	43
Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany	43
HIV testing in primary care in a low‐prevalence area of Northeast England	39
Late diagnosis of HIV infection in Warsaw: Estimating the scale of the problem and demographic trends	37
Telemedicine in HIV health care during the COVID‐19 pandemic: An implementation research study in Buenos Aires, Argentina	32
Perspectives of people with HIV and HIV clinicians on characteristics of antiretroviral treatment and HIV‐related symptoms	31
Potentially inappropriate prescriptions and potential prescription omissions in older people living with HIV	30
HIV cure: Are we going to make history?	27
User‐reported outcomes of long‐acting injectable PrEP with Cabotegravir: Real‐world experience from Milan	23
Aetiology of fever of unknown origin in people living with HIV : A systematic review and meta‐analysis	22
Cellular and humoral response after mRNA SARS‐CoV‐2 vaccination in kidney transplant recipients living with HIV: A cross‐sectional study	22
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV‐specific risk factors; the Archi‐Prevaleat project	21
Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy	21
Effects of transition from paediatric to adult HIV care on virological outcomes in sub‐Saharan Africa: A systematic review and meta‐analysis	20
Areas with high HIV prevalence: A spatial analysis of nationwide claims data in Germany	20
Loneliness and social isolation in people with HIV aged ≥50 years. The No One Alone (NOA)‐GeSIDA study conducted by the GeSIDA 12021 study group	19
	18
Issue Information	18

	18
Assessment of targeted intervention programme under the National AIDS Control Program among men who have sex with men in India	17
Issue Information	17
Using an automated decision support tool to improve HIV prescribing: A feasibility study	17
Exploring the cascade of mental healthcare among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY study	16
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy	16
Issue Information	16
Influence of physical activity on endothelial function in people living with HIV	16
No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people withHIV with profound immunosuppression	15
British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of non‐tuberculous mycobacteria 2024	15
The effect of HIV and mpox co‐infection on clinical outcomes: Systematic review and meta‐analysis	15
Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort	15
Exploring implementation considerations forgeriatric‐HIVclinics: A secondary analysis from a scoping review onHIVmodels of geriatric care	14
Associations between HIV infection and frailty status and its individual components: Are frailty components disproportionally affected?	14
The value of herpes zoster prevention in people aging with HIV: A narrative review	14
Dual drivers of polypharmacy in people with HIV : Quantifying the independent associations of aging and long‐term antiretroviral therapy	14
Prescribing patterns of antiretroviral treatments during pregnancy for women living with HIV in Canada 2004–2020: A surveillance study	14
	13
The first AI‐based Chatbot to promote HIV self‐management: A mixed methods usability study	13
Efficacy and safety of dolutegravir/rilpivirine in real‐world clinical practice. GeSIDA study 1119	13
Changing prevalence and risk factors for Toxoplasma gondii seropositivity and disease in persons with HIV	13
Are there additional adverse effects of testosterone use among men living with HIV?—Data from the PUSH! study	13
Oral Abstracts	13
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium	13
	12
	12
Issue Information	12
Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4	11
Response to letter by Kumar et al. on “Exploring the cascade of mental health care among people with HIV experiencing depressive symptoms in the UK and Ireland: The POPPY	11
AI in medicine: No longer the future, but the present	11
Gender equality in leadership of HIV care cascade clinical trials: A methodological study	11
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis	11
Issue Information	11
	10
“Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study”	10
Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individual	10
Stigma, depression and pillbox return among adults living with HIV in rural Tanzania: A prospective cohort study	10
Access to care and impact on HIV treatment interruptions during the COVID‐19 pandemic among people living with HIV in British Columbia	10
Temporal network analysis of comorbidities among people with HIV in South Carolina	10
Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments	9
Oral Abstracts	9
Knowledge and HIV‐related stigma among Portuguese healthcare professionals: A cross‐sectional analysis	9
De‐simplifying antiretroviral therapy from a single‐tablet to a two‐tablet regimen: Acceptance, patient‐reported outcomes, and cost savings in a multicentre study	9
	9
Predictors of poor health‐related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project	9
Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection	9
	9
	9
Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy	9
Index	9

Late diagnosis of human immunodeficiency virus ( HIV ) and its associated factors in Asian countries: A systematic review	8
Long‐acting cabotegravir and rilpivirine in people with HIV and obesity: Real‐world outcomes from the RELATIVITY	8
Issue Information	8
Availability and stock‐outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda	8
Towards inclusive HIV cure development: Identifying important and acceptable HIV cure attributes a	8
Frequent hepatitis B surface antigen ( HBsAg) clearance during tenofovir therapy in persons with HIV	8
Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV	8
Author Index	8
Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus‐1 (HIV‐1): A systematic literature rev	8
An updated systematic review of HIV‐associated cryptococcal meningitis treatment strategies	8
The role of HIV as a risk modifier for coronary endothelial function in young adults	8
Polypharmacy in HIV : Rethinking what counts and why it matters	8
Blood‐borne virus testing in emergency departments – a systematic review of seroprevalence, feasibility, acceptability and linkage to care	8
Pneumocystis jirovecii pneumonia–Immune reconstitution inflammatory syndrome: A review of published cases	8
Clinical significance and management of low‐level HIV viremia in the era of integrase strand transfer inhibitors	8
HCV incidence in people with HIV in southwest China: A retrospective cohort study (2004–2023)	8
Clinical management of detectable viraemia during CAB / RPV long‐acting therapy: Are really	7
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir‐based dual therapy. Bi‐lipid study	7
Examination of factors associated with mental health of people living with HIV in Kazakhstan: A cross‐sectional study based on the two‐continua model	7
Sex differences in cardiovascular disease and associated factors in people living with HIV : Evidence from All of Us program	7
Y181C ‐associated virologic failure during long‐acting injectable cabotegravir/Rilpivirine in a patient engaged in intensive intravenous Chemsex	7
Impact of the COVID ‐19 pandemic on missed opportunities for diagnosis of HIV infection:	7
Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV	7
Virtual care pathways for people living with HIV: A mixed‐methods systematic review	7
Point‐of‐care nucleic acid testing – a step forward in controlling the HIV epidemic: A review	7
Frailty and frailty screening: A qualitative study to elicit perspectives of people living with HIV and their healthcare professionals	7
Immune response to ART initiation in advanced HIV infection	7
Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study	7
“Real world” efficacy of bulevirtide in HBV/HDV‐related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spa	7
Immunostimulatory effects of Hsp70 fragments and Hsp27 in design of novel HIV‐1 vaccine formulations	7
Cardiovascular risk knowledge stratified by predicted cardiovascular risk level among people living with HIV attending a tertiary	7
Highlights from the 20th European AIDS Conference: 15–18 October 2025, Paris, France	7
Supporting long‐term engagement in HIV clinical care: Learning from the COVID ‐19 pandemic	7
‘We want it all’:ARTpreferences assessed byDesirability ofOutcomeRanking	6
A cross‐sectional comparison of the use of frailty assessment tools in older people living with HIV	6
Intergenerational sex and early sexual debut are associated with HIV infection among transgender women in Paraguay	6
Issue Information	6
Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA	6
The effect of Biktarvy (B/F/ TAF ) on whole‐body insulin sensitivity, lipid and endocrine profile in healthy volunteers	6
	6
Quality of life among people living with HIV aged 50 years and over in Australia: Identifying opportunities to support better ageing	6
Sleep deficiency among people living with human immunodeficiency virus: A growing challenge	6
Potential drug–drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey	6
Issue Information	6
Anticholinergic medications associated with falls and frailty in people with HIV	6
CROI 2024 BHIVA working group summary	6
Incidence and predictors of attrition from HIV treatment among adults living with HIV in high‐caseload facilities following implementation of universal test and treat strategy in	6
Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use	6
Sexual dysfunction care needs of gay, bisexual, and other men who have sex with men living with HIV in Montreal, Canada	6
Strategies to achieve the UNAIDS 95% HIV diagnosis target in Australia: Insights from a multidisciplinary roundtable	6
Issue Information	6
Spatial and temporal trends in HIV / AIDS burden among South Asian countries from 1990 to 2021: A	6
Scars are frequently found as late sequelae in individuals affected by the 2022 mpox outbreak	6
Late diagnosis of HIV: An updated consensus definition	6
Prevalence of, risk factors for, and target organ damage from metabolic syndrome among people living with HIV on ART: A cross‐sectional analysis in Chongqing, China	6
Implementing the National Vaccination Plan in people with HIV in Italy	5
Natural occurrence of drug resistance mutations to the HIV ‐1 capsid inhibitor lenacapavir	5
Factors associated with uptake of gynaecological care and cervical cancer screening among women in the Swiss HIV Cohort Study	5
Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin‐based regimen: A retrospective observational case series	5
The outcomes of anxiety and depression symptom screening in a population with HIV : Insights from an HIV	5
Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C	5
Issue Information	5
	5
Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)	5
Implementation of frailty screening for older people living with HIV in Brighton, UK	5
Worldwide changes in HIV ‐related stigma among people living with HIV : A cross‐temporal meta‐anal	5
Trends in preterm birth in women living with HIV in Switzerland over the last three decades: A multicentric, prospective, cohort study	5
Correction to ‘Abstracts of the 19th European AIDS Conference (# EACS2023 ), October 18–21, 2023,	5
Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia	5
Issue Information	5
Optimizing statin prescriptions for people living with HIV: Evidence for improved communication and shared care between primary care and specialist HIV	5
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III stud	5
Real‐world efficacy of bictegravir/emtricitabine/tenofovir alafenamide regimen in patients infected with HIV‐1 sub‐subtype A6 harbouring the L74I mutation	5
	5
Issue Information	5
Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment	5
Treatment durability, satisfaction and quality of life in virologically suppressed HIV ‐1 people switching to doravirine: Results from the French stu	5
Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with	5
Sexually transmitted and blood‐borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder: Findings from a Canadian pragmatic rand	5
Cost of non‐communicable diseases in people living with HIV in the Central Denmark Region	5

What are the predictors of change in multimorbidity among people with HIV? A longitudinal observational cohort study	5
	5
Impact of the COVID‐19 pandemic on the HIV care continuum and associated factors in middle‐income countries: A mixed‐methods systematic review	5
One for all, all for one: neuro‐HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV	5
Issue Information	5
SARS‐CoV‐2 vaccine immunogenicity for people living with HIV: A systematic review and meta‐analysis	5
High mortality among patients hospitalized for drug‐resistant tuberculosis with acquired second‐line drug resistance and high HIV prevalence	5
Factors influencing the quality of life and social skills of children living with HIV: A case–control study	5
	4
Switch to a raltegravir‐based antiretroviral regimen in people with HIV and non‐alcoholic fatty liver disease: A randomized controlled trial	4
	4
PrEP for women in Europe: a systematic literature review	4
Issue Information	4
Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025	4
Risk factors, management, and HPV genotyping of vulvar intraepithelial neoplasia ( VIN ) in women	4
Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96	4
Comorbidities, comedications and potential drug–drug interactions among people living with HIV in China	4
Hypertriglyceridaemia and gender differences in the risk of major adverse cardiovascular events in people with HIV : A single‐centre retrospective lo	4
	4
Issue Information	4
BMI as a predictor of high fasting blood glucose among people living with HIV in the Asia‐Pacific region	4
Issue Information	4
	4
Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real‐life experience from a French cohort (2019–2023)	4
Cytomegalovirus infection among people living with HIV in Sweden: Case profiles, treatment strategies and patient outcomes at Karolinska University Hospital 2010–2020	4
	4
	4
Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV	4
The impact of accumulating immune adaptation in circulating strains of HIV ‐1	4
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies	4
Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms	4
Low‐level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression	4
	4
	4
Issue Information	4
Late diagnosis of HIV in 2022: Why so little change?	4
Frailty in people 50 years or older living with HIV: A sex perspective	4
An overview of consent requirements for HIV and viral hepatitis B and C testing in Europe	4
Individual characteristics and time‐updated factors associated with antiretroviral treatment interruptions among people living with HIV in British Co	4
HIV treatment strategies across Central, Eastern and Southeastern Europe: New times, old problems	4
Recognizing International Women's Day 2026	4
Erratum	4
Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts	4
Molecular epidemiological analysis and investigation of antiretroviral drug resistance profile, including capsid inhibitors, among treatment‐naïve individuals with HIV	4
HIV and fracture: Risk, assessment and intervention	4